Cupps Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cupps Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,751	Closed	-$471K	–	220
2015 Q4	$471K	Buy	+3,751	New	+$453K	0.07%	129
2015 Q3	–	Sell	-3,410	Closed	-$421K	–	208
2015 Q2	$421K	Sell	3,410 -255	-7%	-$32.1K	0.04%	137
2015 Q1	$432K	Sell	3,665 -23,775	-87%	-$2.85M	0.04%	152
2014 Q4	$3.26M	Sell	27,440 -11,708	-30%	-$1.32M	0.29%	92
2014 Q3	$4.4M	Buy	39,148 +20,643	+112%	+$1.97M	0.41%	90
2014 Q2	$1.75M	Sell	18,505 -18,250	-50%	-$1.28M	0.14%	131
2014 Q1	$2.6M	Buy	36,755 +31,204	+562%	+$2.47M	0.2%	118
2013 Q4	$412K	Buy	+5,551	New	+$387K	0.03%	130
2013 Q3	–	Sell	-11,053	Closed	-$884K	–	213
2013 Q2	$884K	Buy	+11,053	New	+$814K	0.07%	117

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cupps Capital Management's VRTX Position: Q1 2016 in Review

Cupps Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 3,751 shares — an estimated $471K sold.

Cupps Capital Management first reported a position in VRTX in Q2 2013 and held it in 9 quarters. The position peaked at $4.4M in Q3 2014. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Cupps Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Cupps Capital Management sold 3,751 Vertex Pharmaceuticals shares in Q1 2016, an estimated $471K.
Cupps Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Cupps Capital Management's Vertex Pharmaceuticals position peaked at $4.4M in Q3 2014.
503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Cupps Capital Management's 13F filing for Q1 2016, filed 12 May 2016.